Allergan and Editas announce $90M CRISPR deal
There really is enough CRISPR to go around. On Tuesday Allergan and Editas struck a deal to apply the gene-editing approaching in certain ocular conditions, including Leber congenital amaurosis.
There really is enough CRISPR to go around. On Tuesday Allergan and Editas struck a deal to apply the gene-editing approaching in certain ocular conditions, including Leber congenital amaurosis.